Multiplex Nontargeted Framework Enables Tracking Metabolic Profile of Oxymetholone and Methasterone In Vivo at Nanogram Level by GC-Orbitrap-HRMS for Antidoping Purpose
Analytical Chemistry · 2025
DOI: 10.1021/acs.analchem.4c06026 ↗Kurz gefasst
Fachartikel in der Zeitschrift Analytical Chemistry, 2025. Verfasst von Siying Zheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai University of Sport, 399 Changhai Road, Shanghai 200438, China. Hauptthemen laut MEDLINE: Doping in Sports, Oxymetholone, Substance Abuse Detection, Anabolic Agents. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, the Collaborative Innovation Capacity Construction Project of Shanghai University of Sport.
Abstract (Originalsprache)
Oxymetholone and methasterone are anabolic androgenic steroids prohibited by the World Anti-Doping Agency (WADA) for both in-competition and out-of-competition use. Detecting metabolites of exogenous steroids is crucial for establishing doping violations, making the study of these metabolites essential in antidoping efforts. This study investigated the urinary metabolic profiles of oxymetholone and methasterone using gas chromatography-orbitrap high-resolution mass spectrometry (GC-Orbitrap-HRMS) in nanogram level by utilizing a novel multiplex nontargeted framework protocol. Healthy volunteers each ingested one tablet of the drug, and urine samples were collected over 50 days in postadministration phase. The complete detection of the three fractions (free fraction, glucuronide fraction, and sulfate fraction) of the metabolites was carried out. The GC-Orbitrap-HRMS full-scan mode was employed to detect postadministration urine samples, comparing these with preadministration baseline urine samples to identify newly formed substances. Electron ionization (EI) mass spectra were used to infer possible metabolite structures, leading to the discovery of three novel metabolites of oxymetholone and two novel metabolites of methasterone. Notably, the newly identified oxymetholone metabolite, 2-methylene-17α-methyl-androstane-16ξ,17β-diol-3-one (O-M6), was detectable as a glucuronide conjugate up to 4 days after administration. The methasterone metabolite, 18-nor-17β-hydroxymethyl-2α,17α-dimethyl-5α-androst-13-en-3-one (M-M4), exhibited prolonged detectability as a glucuronide conjugate, being present in urine samples from both volunteers up to 50 days after administration. These findings have significant implications for antidoping purpose, providing extended detection windows for these anabolic steroids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai University of Sport, 399 Changhai Road, Shanghai 200438, China.
- Shanghai Anti-doping Laboratory, 900 Jiangwancheng Road, Shanghai 200438, China.
ORCID-Profile: Lei Liao
Förderung
- National Natural Science Foundation of China
- the Collaborative Innovation Capacity Construction Project of Shanghai University of Sport
Zitieren
APA
Zheng, S., Ge, Y., Fang, X., Liu, M., Sun, H., Deng, X., & Liao, L. (2025). Multiplex Nontargeted Framework Enables Tracking Metabolic Profile of Oxymetholone and Methasterone In Vivo at Nanogram Level by GC-Orbitrap-HRMS for Antidoping Purpose. Analytical Chemistry. https://doi.org/10.1021/acs.analchem.4c06026
Vancouver
Zheng S, Ge Y, Fang X, Liu M, Sun H, Deng X, et al. Multiplex Nontargeted Framework Enables Tracking Metabolic Profile of Oxymetholone and Methasterone In Vivo at Nanogram Level by GC-Orbitrap-HRMS for Antidoping Purpose. Analytical Chemistry. 2025. doi:10.1021/acs.analchem.4c06026
BibTeX
@article{Zheng2025,
author = {Zheng, Siying and Ge, Yuqi and Fang, Xian and Liu, Mengpan and Sun, Haoyi and Deng, Xiaojun and Liao, Lei},
title = {Multiplex Nontargeted Framework Enables Tracking Metabolic Profile of Oxymetholone and Methasterone In Vivo at Nanogram Level by GC-Orbitrap-HRMS for Antidoping Purpose},
journal = {Analytical Chemistry},
year = {2025},
doi = {10.1021/acs.analchem.4c06026}
}
EUVIMED